Insight

Sankalp Arora: Describing outcomes of PICALM at EHA24

Photo taken from Sankalp Arora/X

Jun 17, 2024, 16:36

Sankalp Arora: Describing outcomes of PICALM at EHA24

Sankalp Arora, Hematology/Oncology Fellow at the MD Anderson Cancer Center, shared on X/Twitter:

“Excited to be presenting retrospective data from MD Anderson Cancer Center at EHA24 describing outcomes of PICALM::MLLT10 fusion acute leukemias!

Key takeaways:

– PICALM::MLLT10 fusion leads to acute leukemias with myeloid/lymphoid/mixed phenotype
– Immature cells with mixed immunophenotype and lineage infidelity
– High frequency of Extramedullary disease
– Low response rates to standard induction therapies.”

Visit the article website.
Source: Sankalp Arora/X

cancer EHA24 Extramedullary disease fusion acute leukemias Immature cells immunophenotype MD Anderson Cancer Center MLLT10 OncoDaily Oncology PICALM Sankalp Arora standard induction therapies

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage